We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+8%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.32B
AUM Growth
-$22.5M
Cap. Flow
-$89.9M
Cap. Flow %
-6.81%
Top 10 Hldgs %
48.68%
Holding
85
New
25
Increased
22
Reduced
17
Closed
16

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62.7M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$57.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.5M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33.4M
5
GPCR icon
Structure Therapeutics
GPCR
+$22.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$67.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$65.7M
3
GMED icon
Globus Medical
GMED
+$61.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$53.5M
5
ONC
BeOne Medicines Ltd
ONC
+$49.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
26
Liquidia Corp
LQDA
$7.95B
$15M 1.14%
1,500,000
-330,000
-18% -$3.6M
A icon
27
Agilent Technologies
A
$39.9B
$14.8M 1.13%
+100,000
New +$13.7M
BMY icon
28
Bristol-Myers Squibb
BMY
$131B
$12.9M 0.98%
250,000
-250,000
-50% -$11.7M
GSK icon
29
GSK
GSK
$104B
$12.3M 0.93%
+300,000
New +$12.3M
BCAX
30
Bicara Therapeutics
BCAX
$1.81B
$10.8M 0.82%
+425,000
New +$10.8M
DNTH icon
31
Dianthus Therapeutics
DNTH
$6.15B
$10.8M 0.82%
395,000
-205,000
-34% -$5.71M
CRNX icon
32
Crinetics Pharmaceuticals
CRNX
$8.9B
$10.5M 0.79%
+205,000
New +$10.6M
ITOS
33
DELISTED
iTeos Therapeutics
ITOS
$10.5M 0.79%
1,025,000
-725,000
-41% -$11.1M
APLT
34
DELISTED
Applied Therapeutics
APLT
$9.73M 0.74%
1,145,000
-4,285,000
-79% -$25.3M
NRIX icon
35
Nurix Therapeutics
NRIX
$2.62B
$9.55M 0.72%
425,000
-75,000
-15% -$1.7M
SNY icon
36
Sanofi
SNY
$104B
$8.64M 0.66%
+150,000
New +$8.1M
BRKR icon
37
Bruker
BRKR
$7.8B
$8.63M 0.65%
+125,000
New +$8.07M
APGE icon
38
Apogee Therapeutics
APGE
$10.2B
$8.02M 0.61%
+136,500
New +$6.54M
ZYME icon
39
Zymeworks
ZYME
$1.7B
$7.72M 0.59%
615,000
+175,000
+40% +$1.91M
LXEO icon
40
Lexeo Therapeutics
LXEO
$357M
$7.68M 0.58%
850,000
+10,000
+1% +$119K
TARS icon
41
Tarsus Pharmaceuticals
TARS
$2.85B
$7.56M 0.57%
+230,000
New +$6.46M
ANRO icon
42
Alto Neuroscience
ANRO
$1.11B
$7.44M 0.56%
650,000
+30,000
+5% +$367K
BDX icon
43
Becton Dickinson
BDX
$48.8B
$7.23M 0.55%
+30,000
New +$7.03M
MDGL icon
44
Madrigal Pharmaceuticals
MDGL
$11.8B
$6.37M 0.48%
+30,000
New +$7.67M
LEGN icon
45
Legend Biotech
LEGN
$3.73B
$6.09M 0.46%
+125,000
New +$6.66M
FATE icon
46
Fate Therapeutics
FATE
$290M
$5.9M 0.45%
1,685,000
-315,000
-16% -$1.23M
LKFT
47
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$5.18M 0.39%
180,000
– –
URGN icon
48
UroGen Pharma
URGN
$2.22B
$5.08M 0.39%
+400,000
New +$5.94M
GLUE icon
49
Monte Rosa Therapeutics
GLUE
$1.33B
$4.93M 0.37%
930,000
+40,000
+4% +$202K
GERN icon
50
Geron
GERN
$1.01B
$4.77M 0.36%
+1,050,000
New +$4.77M
1
2
3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Vestal Point Capital held 85 positions worth $1.32B, down 1.7% from $1.34B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Vestal Point Capital withdrew a net $89.9M in Q3 2024, closing 16 positions and reducing 17 holdings. Its most notable exit was Globus Medical, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 100% a quarter earlier.

Against the trend, Vestal Point Capital opened a new position in Agios Pharmaceuticals worth $33.8M.

  • Vestal Point Capital's largest Q3 2024 buy was Agios Pharmaceuticals: 760,000 shares worth $33.8M.
  • Vestal Point Capital added most to Insmed in Q3 2024, an estimated $62.7M increase.
  • Vestal Point Capital's biggest Q3 2024 reduction was Ascendis Pharma A/S, cutting an estimated $67.5M.
  • Vestal Point Capital fully exited Globus Medical in Q3 2024, selling an estimated $61.6M.
  • Vestal Point Capital's ten largest holdings make up 49% of its $1.32B portfolio in Q3 2024.
  • Vestal Point Capital opened 25 new positions and closed 16 in Q3 2024.
  • Vestal Point Capital's portfolio value fell 1.7% quarter-over-quarter to $1.32B.

Based on Vestal Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.